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Abstract
Introduction: Infectious complications represent a major cause of morbidity and mortality in
patients with chronic lymphocytic leukemia (CLL). The etiology is postulated to be secondary to
aberrations in cell-mediated immunity, as well as to therapy-related immunosuppression.
Hypogammaglobulinemia, which occurs in virtually all patients with CLL, may be profound and
correlates with disease duration and stage. Intravenous immunoglobulin (IVIG) therapy has been
used successfully to prevent and treat infections in this cohort of patients. However IVIG
administration and treatment is not benign and should be used with caution given the potential
manifestations of thromboembolic complications. High concentration and rapid infusion rate of the
IVIG, as well as increased dose and osmolarity of the solution are thought to predispose to
thrombotic events. Serum viscosity is the implicated mechanism for compromised blood flow and
predisposition of high-risk patients to cardiovascular or cerebrovascular infarction. We report a
case of IVIG related thromboembolic manifestations in a CLL patient, to highlight the importance
of risk stratifying patients prior to treatment administration.
Case presentation: We present a 55-year-old Caucasian man with CLL who presented to our
clinic with neutropenic fevers following a cycle of chemotherapy. Laboratory parameters revealed
hypogammaglobulinemia prompting IVIG administration. Shortly thereafter, he developed a
massive cascade of thromboembolic phenomena precipitating his demise.
Conclusion: The current consensus surrounding IVIG is that of a relatively safe treatment, with
minor adverse effects such as hypertension, fever and chills, nausea, myalgias, or headache.
However our report highlights the importance of proceeding with caution in the application of this
therapy, as it's proclivity for thrombotic complications has not been fully elucidated in patients with
underlying malignancies. Pre-existing thrombogenic risk factors should be carefully evaluated in
patients undergoing treatment with IVIG. Clinical evaluation, with careful attention to vascular
history and underlying co-morbidities can potentially unmask the high-risk patient where IVIG
could be lethal.
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The clinical application of immunoglobulins as a thera-
peutic agent dates back to more than a century when the
first Nobel laureate, Emil Behring, observed that immune
sera could ameliorate toxin-mediated diseases [1-3].
Immunoglobulins were first used for prophylaxis and
treatment of infectious diseases. Initially preparations
were injected intramuscularly with adverse limitation of
painful myalgias and skin hypersensitivity reactions due
to local proteolytic degradation. An intravenous applica-
tion was not possible secondary to aggregates of purified
immunoglobulins, leading to severe adverse reactions
precipitated by activation of the complement cascade. The
advent of new purification technologies allowed for the
elimination of aggregates, and preparations of immu-
noglobulins for intravenous use became available [1-4].
In 1981 during treatment of two children with hypogam-
maglobulinemia and coincidental idiopathic thrombocy-
topenic purpura (ITP), physicians in Switzerland
observed a reproducible increase in the platelet count fol-
lowing IVIG treatment. This clinical observation and fol-
low up systemic investigations further intensified the
widespread clinical use of IVIG as a potential immune
modulatory agent [1].
Today, Intravenous immunoglobulin (IVIG) is used in a
broad spectrum of autoimmune, inflammatory, and pri-
mary and secondary immunodeficiencies. The efficacy has
been demonstrated in several control studies [5,6]. IVIG is
a blood product prepared from the serum of between
1,000 and 15,000 donors per batch. The mechanism of
action validated by in-vitro models is exerted by a com-
bined effect on autoantibodies, complement activation,
cytokines, and saturation of Fc receptors on tissue macro-
phages [1-3].
IVIG is considered a relatively safe treatment, which has
contributed to its wide appeal. Most of the adverse events
associated with IVIG are mild and transient. They com-
monly include fevers, chills, flushing, headaches, myal-
gias, blood pressure changes, tachycardia, and
anaphylactic reactions, which are more pronounced in
IgA-deficient patients [4-7]. Nevertheless, Brannagan et al.
(1996) have reported a number of side effects. These were
generally self-limited, but included serious complications
such as deep venous thrombosis, pulmonary embolism,
myocardial infarction, and stroke.
The mechanism of thromboembolic complications is pos-
tulated to be secondary to hyperviscosity, especially in
patients having risk factors including advanced age, previ-
ous thromboembolic diseases, diabetes mellitus, hyper-
tension, dyslipidemia, or those receiving high-dose IVIG
at a rapid infusion rate [6,7].
Our patient in this case report manifested symptoms of
expressive aphasia, weakness of this bilateral upper and
lower extremities, and chest discomfort shortly following
IVIG administration. As a result, we present this case
report to demonstrate the importance of screening
patients with underlying co-morbidities, especially malig-
nant conditions and their higher predisposition for
thromboembolism, prior to initiation of IVIG. Familiarity
with adverse effects of IVIG can empower patients and
physicians in their assessment of the risks and benefits
prior to the use of this treatment.
Case presentation
We present a case of a 55-year-old Caucasian man with a
past medical history significant for Chronic Lymphocytic
Leukemia (CLL) and Melanoma, diagnosed in 2006 and
2008 respectively, who presented to our Cancer Center
complaining of a one-day history of persistent fevers and
chills. The patient was visiting from out of state and was
concerned about a potential infection. He had completed
his 4th cycle of chlorambucil (40 mg per square meter,
given orally every 28 days) for his CLL two weeks prior.
The patient was status post surgical excision for a stage
IIIA melanoma discovered in the left axilla with no further
adjuvant treatment. He was scheduled to travel exten-
sively over the course of the proceeding month and
requested an additional course of antibiotics.
On review of systems, he noted progressive fatigue and
anorexia. He had started a prescription for levofloxacin
prior to the clinic visit. The patient had no known drug
allergies. The patient denied any tobacco or alcohol use.
He was employed in an office setting. There was no perti-
nent family history. The patient had a temperature of 38
degrees Celsius. Physical exam was remarkable for an
enlarged spleen, approximately 3 finger-breadths below
the costal margin. Laboratory parameters revealed a white
blood cell count of 21,500 (normal 4500-11,000/mm3),
a hemoglobin of 10.8 g/dl (normal 11-15 g/dl), and a
platelet count of 170,000 (normal 150,000-400,000/
mm3). His absolute neutrophil count (ANC) was 430
(normal 1,500 to 8,000/mm3). Further a quantitative
immunoglobulin panel was consistent with hypogamma-
globulinemia: IgG level was 309 L (normal 562-1585 mg/
dl), IgM 9.0 L (normal 30-246 mg/dl), and IgA was 10 L
(normal 72-372 mg/dl).
The patient was subsequently admitted to our hospital for
evaluation and treatment of febrile neutropenia. We
elected to administer 30 grams of IVIG (0.4 g/kg) as a
means of enhancing his immunity in the context of recent
exposure to chemotherapy and his hypogammaglobuline-
mia. The patient had previously tolerated multiple infu-
sions of IVIG without any adverse reactions. We
premedicated the patient with acetaminophen, hydrocor-Page 2 of 4
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the IVIG infusion, the patient began to complain of head-
aches, shortness of breath with accompanying chest pain,
and weakness of his bilateral upper and lower extremities.
A complete cardiac and neurologic assessment was imme-
diately initiated. The patient was found to have a myocar-
dial infarction with a troponin elevation of 15.2 ng/ml
and 13.3 ng/ml (normal 0.00-0.15 ng/ml) for the first two
sets of his cardiac enzymes respectively, with a clearance
of the enzymes by his third set. The EKG revealed ST-T
wave changes consistent with myocardial ischemia in the
inferior and anterolateral regions. An echocardiogram was
consistent with a mural thrombus (Figure 1) visualized in
the left ventricular apex. There was mild global left ven-
tricular hypokinesis, with inferior and inferolateral wall
motion abnormalities consistent with myocardial infarc-
tion. In addition, an MRI of the brain (Figures 2, 3 and 4)
delineated evolving cerebral infarcts seen within the left
posterior MCA distribution (Figure 2), bilateral high pari-
etal loops (Figure 3), and bilateral occipital lobes (Figure
4). There was no evidence of significant mass effect or
hemorrhagic transformation.
Furthermore, the patient began to experience a change in
his mental status. A Neurology consult was obtained and
the assessment attributed his waxing and waning con-
sciousness to the continued watershed infarcts that were
present. Nevertheless an EEG study was performed which
delineated periodic lateralized epileptiform discharges
consistent with seizure like activity. The patient was sub-
sequently placed on intravenous levetiracetam with no
improvement in his mental status. Shortly thereafter he
had increasing respiratory requirements, and the decision
was made to forgo intubation at the request of the family
secondary to the patient's pre-determined request to never
be placed on a ventilator.
Conclusion
To date, IVIG has more often been considered a safe med-
ication, with minor adverse effects such as hypertension,
fever and chills, nausea, myalgia or headache. However,
Mural Thrombus in Left VentricleFigure 1
Mural Thrombus in Left Ventricle.
Infarct Left Posterior MCA DistributionFigure 2
Infarct Left Posterior MCA Distribution.
Infarct Bilateral Parietal LobesFigure 3
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maglobulinemia associated malignancies, and various
autoimmune disorders, the potential for severe sideeffects
such acute renal tubular necrosis, aseptic meningitis, ana-
phylaxis in patients with IgA deficiencies, and thrombotic
manifestations need to be considered.
In concordance with previous reports [1-10], we docu-
mented a close temporal association between a cardiovas-
cular and cerebrovascular insult secondary to IVIG
infusion. Our patient suffered a myocardial infarction
(MI) and stroke within 24 hours of the IVIG infusion. Fur-
thermore, whereas rapid infusion protocols have previ-
ously been identified as a possible thomboembolic risk
factor, our patient received standard doses of IVIG at con-
ventional infusion rates.
The pattern of stroke in multiple vascular territories (Fig-
ures 2, 3 and 4) on MRI imaging portends to a throm-
boembolic mechanism of stroke, rather than occlusion of
atherosclerotic cerebral arteries or small vessel disease. A
possible mechanism of stroke is the introduction of clot-
ting factors and/or vasoactive cytokines that would trigger
the thrombotic cascade and lead to in situ thrombosis and
embolism. Alternatively, elevated plasma serum viscosity
has been proposed as a likely mechanism by some [3].
Our case report indicates that patients should be moni-
tored closely for these types of adverse events during any
period of IVIG therapy. In patients presenting with predic-
tive factors of thrombotic complications, IVIG should be
prescribed cautiously, after judiciously weighing the risk-
benefit considerations.
Consent
In terms of obtaining consent for publication, all reason-
able attempts to gain consent have been made. The
patient's next of kin reside overseas and as a result estab-
lishing contact has been unsuccessful. We declare that the
patient is anonymous and we have no reason to believe
that the patient or their family would object to this publi-
cation. We briefly mentioned the potential of writing up a
case report when the patient was still alive, and the family
felt that if it would benefit medical practice, they would
support our efforts.
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